Photodynamic Therapy Market Size, Share, and Growth Forecast, 2026 - 2033

The global photodynamic therapy market size is expected to reach US$4.1 billion in 2026 and US$6.6 billion at a CAGR of 7.2% during the forecast period from 2026 to 2033, driven by rising cancer incidence, growing preference for minimally invasive treatments, and increasing availability of advanced photosensitizers and light-based devices. North America leads due to its established oncology infrastructure and reimbursement policies. At the same time, Asia Pacific is the fastest-growing region, driven by rising healthcare investments and expanding adoption of cancer treatments.

Driver - Innovation in Drug-Device Combinations

Innovation in drug-device combinations is increasingly driving the Photodynamic Therapy (PDT) market, as the approach pairs a photosensitizing drug with a light-delivery device to enhance selectivity and outcomes. The first approved PDT regimen, the drug-device combo of Porfimer sodium (Photofrin) plus laser light, was approved by the U.S. Food and Drug Administration (FDA) in 1995 for esophageal cancer, and subsequently for other indications.

Recent clinical and bench research show that integrating targeted delivery systems (e.g., nanosyringes delivering photosensitizers and oxygen) with real-time light dosimetry markedly improves efficacy in solid tumors. For example, a U.S. SBIR-funded project is developing hardware/software that integrates real-time dosimetry for interstitial PDT of deep tumors. Moreover, a meta-analysis in ophthalmology found that combining PDT with anti-VEGF drugs achieved polyp regression rates up to those with monotherapy. Together, the data show that drug-device combinations in PDT not only enhance therapeutic precision and outcomes but also broaden the scope of treatable indications, fueling market expansion.

Restraint - Lack of Standardization of Treatment Protocols

Lack of standardized PDT protocols remains a key restraint: approved photosensitizers and devices have widely varying dosing, incubation times, light wavelengths, and dosimetry, which undermines reproducibility and reimbursement. For example, FDA approvals for PDT agents span decades (Photofrin/porfimer sodium approved 1995; Levulan/5-ALA approved 1999), yet clinical reports show inconsistent parameter reporting across trials. ClinicalTrials.gov lists dozens of PDT studies, reflecting active investigation but heterogeneous designs that impede meta-analysis.

Peer-reviewed reviews and systematic summaries repeatedly call out this heterogeneity and the need for consensus on dose, light source, and endpoint measurement to allow pooled evidence and guideline development. State/regional reviews likewise note that variable protocols prevent demonstration of superiority among modalities. That combination, legacy approvals, many small heterogeneous trials, and inconsistent dosimetry, slows guideline uptake, limits payer coverage, and restrains wider clinical adoption of PDT.

Opportunity - Development of Novel Photosensitizers

Development of novel photosensitizers offers a transformative opportunity in the Photodynamic Therapy (PDT) market by addressing key limitations of existing agents, such as shallow light penetration and prolonged photosensitivity. Modern research funded by the U.S. National Institutes of Health (NIH) and the European Commission focuses on next-generation chlorins, bacteriochlorins, and nanoparticle-based photosensitizers that can be activated by near-infrared (NIR) light, enabling deeper tissue penetration. For instance, NIH data show more than 70 ongoing PDT-related grants targeting nanocarrier or oxygen-enhanced photosensitizers, reflecting strong translational interest.

Clinical trials registered demonstrate increasing exploration of photosensitizers linked to monoclonal antibodies and immune-stimulatory agents, aiming to combine PDT with immunotherapy. These innovations promise improved tumor selectivity, faster clearance, and reduced side effects, expanding PDT’s utility beyond dermatology and oncology into antimicrobial, ophthalmic, and cardiovascular applications, thus creating substantial commercial and clinical growth opportunities.

Product Type Insights

Photosensitizer drugs are anticipated to account for approximately 63.4% of the market share in 2026, supported by their essential role in generating the photochemical reaction that destroys targeted abnormal cells. Widely used agents such as porfimer sodium (Photofrin), aminolevulinic acid (Levulan Kerastick), and methyl aminolevulinate (Metvixia) support applications across oncology and dermatology. Their established clinical use and continued development of next-generation photosensitizers are strengthening segment growth.

Photodynamic therapy devices are the fastest-growing product segment, driven by advancements in LED-based light sources, laser systems, fiber-optic delivery, and real-time dosimetry technologies. For example, newer PDT systems are being developed to provide more precise light intensity and treatment-area control, improving therapeutic consistency. Growing adoption of portable and specialized light-delivery devices in dermatology and oncology is expected to further accelerate segment expansion.

Indication Insights

Cancer is anticipated to remain the leading indication segment, accounting for approximately 55.1% of the market share in 2026, driven by the increasing global cancer burden and PDT's ability to selectively target malignant and precancerous tissues while limiting damage to surrounding healthy cells. PDT is used in applications including esophageal cancer, non-small cell lung cancer, and certain skin cancers. Growing clinical research into PDT for head and neck, brain, and other solid tumors is further supporting segment growth.

Skin conditions are projected to be the fastest-growing indication segment, supported by rising demand for minimally invasive dermatological treatments and the expanding use of PDT for actinic keratosis, acne, and certain superficial skin cancers. For example, aminolevulinic acid-based PDT is widely used for actinic keratosis, while research is expanding into acne and other inflammatory skin conditions. Increasing awareness of non-surgical cosmetic and dermatological therapies, combined with improvements in light-delivery technologies, is expected to accelerate adoption of PDT for skin conditions.

North America Photodynamic Therapy Market Trends

North America is expected to dominate the photodynamic therapy market with a 38.8% share in 2026, supported by advanced healthcare infrastructure, high cancer prevalence, and strong adoption of minimally invasive treatments. The U.S. is projected to record more than 2 million new cancer cases in 2025, supporting demand for targeted therapies such as PDT. FDA approvals of photosensitizers including porfimer sodium and aminolevulinic acid, alongside NIH-backed research, continue to strengthen clinical adoption across oncology and dermatology.

U.S. Photodynamic Therapy Market Trends

The U.S. represents the region's major PDT market, supported by established regulatory pathways, specialized dermatology centers, and continued development of drug-device combinations. Biofrontera's Ameluz® and BF-RhodoLED® exemplify this trend, combining a topical photosensitizer with a dedicated light source for PDT. The company's expansion of Ameluz® applications and continued development of RhodoLED® devices reflect growing demand for more controlled and convenient PDT treatment options.

Europe Photodynamic Therapy Market Trends

Europe is supported by strong regulatory frameworks, clinical research, and established use of PDT in oncology and dermatology. The region's PDT ecosystem is also expanding through product innovation and broader indications. For example, Germany-based Biofrontera has expanded the European application of Ameluz®, including approval for actinic keratosis on the extremities and trunk/neck and subsequent development of artificial-daylight PDT. These developments are broadening patient access and supporting wider adoption of dermatological PDT across European markets.

Germany Photodynamic Therapy Market Trends

Germany is an important European market due to its established dermatology infrastructure and strong presence of PDT manufacturers. Biofrontera's Ameluz® has achieved particularly strong penetration in the country, with the company reporting a 73% market share in Germany in the first half of 2025. The expansion of artificial-daylight PDT and the availability of dedicated BF-RhodoLED® systems are helping increase treatment flexibility and reinforce Germany's position as a major European PDT market.

Asia Pacific Photodynamic Therapy Market Trends

Asia Pacific is the fastest-growing region, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing investment in advanced oncology treatments. China, Japan, and India are seeing greater interest in minimally invasive cancer and dermatological therapies, while regulatory development and clinical research are supporting wider PDT adoption. The region's large patient population and increasing access to specialized cancer-care facilities create substantial opportunities for photosensitizer and light-device manufacturers.

China Photodynamic Therapy Market Trends

China is emerging as a key Asia Pacific growth market, supported by its large oncology patient base, expanding hospital infrastructure, and increasing focus on advanced cancer therapies. Growing clinical research into PDT and photosensitizer-based treatments is helping build local expertise, while the country's expanding medical technology ecosystem creates opportunities for domestic and international PDT companies. This combination of healthcare investment and unmet demand is expected to accelerate PDT adoption across oncology and dermatology.

The global photodynamic therapy market is expanding as manufacturers advance photosensitizer formulations, device precision, and light delivery systems. Leading players focus on improving treatment safety and selectivity, while emerging firms explore novel photosensitizers and drug-device combinations. Strategic collaborations, clinical research investments, and regulatory approvals are driving PDT adoption in oncology, dermatology, and ophthalmology.

Key Industry Developments:

• In September 2025, Biofrontera Inc. announced that the last patient had completed participation in its Phase 3 clinical study evaluating Ameluz® (aminolevulinic acid HCl) topical gel, 10%, used in Photodynamic Therapy (PDT) for treating actinic keratoses (AK) on the extremities, neck, and trunk.
• In September 2025, Soligenix announced that it had expanded its European Medical Advisory Board to strengthen clinical guidance and research strategies for cutaneous T-cell lymphoma (CTCL). The expanded board included leading dermatology and oncology experts from across Europe, aiming to support ongoing development of Soligenix’s Photodynamic Therapy (PDT) and other targeted treatments for rare skin lymphomas.